Clopidogrel 150 vs. 75 mg day−1 in patients undergoing percutaneous coronary intervention: a meta‐analysis

Sibbing, 2010, Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel‐treated patients: initial evidence of a therapeutic window, J Am Coll Cardiol, 56, 317, 10.1016/j.jacc.2010.03.048

Smith, 2006, J Am Coll Cardiol, 47, 216, 10.1016/j.jacc.2005.11.025

Porto, 2009, Platelet P2Y12 receptor inhibition by thienopyridines: status and future, Expert Opin Investig Drugs, 18, 1317, 10.1517/13543780903176415

Arméro, 2010, Intra‐individual variability in clopidogrel responsiveness in coronary artery disease patients under long term therapy, Platelets, 21, 503, 10.3109/09537104.2010.499483

Ben‐Dor, 2009, Assessment, mechanisms, and clinical implication of variability in platelet response to aspirin and clopidogrel therapy, Am J Cardiol, 104, 227, 10.1016/j.amjcard.2009.03.022

Cuisset, 2006, Benefit of a 600‐mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non‐ST‐segment elevation acute coronary syndrome undergoing coronary stenting, J Am Coll Cardiol, 48, 1339, 10.1016/j.jacc.2006.06.049

Angiolillo, 2004, High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability, Eur Heart J, 25, 1903, 10.1016/j.ehj.2004.07.036

Patti, 2005, Circulation, 111, 2099, 10.1161/01.CIR.0000161383.06692.D4

McRae, 2006, Effect of patient’s sex on risk of recurrent venous thromboembolism: a meta‐analysis, Lancet, 368, 371, 10.1016/S0140-6736(06)69110-1

Angiolillo, 2007, Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study, Circulation, 115, 708, 10.1161/CIRCULATIONAHA.106.667741

von Beckerath, 2007, A double‐blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days, Eur Heart J, 28, 1814, 10.1093/eurheartj/ehl489

Abuzahra, 2008, Comparison of higher clopidogrel loading and maintenance dose to standard dose on platelet function and outcomes after percutaneous coronary intervention using drug‐eluting stents, Am J Cardiol, 102, 401, 10.1016/j.amjcard.2008.03.073

Aleil, 2008, Clopidogrel 150 mg day−1 to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP‐02 (Vasodilator‐Stimulated Phosphoprotein‐02) randomized study, JACC Cardiovasc Interv, 1, 631, 10.1016/j.jcin.2008.09.004

Nguyen, 2009, Week‐long high‐maintenance dose clopidogrel regimen achieves better platelet aggregation inhibition than a standard loading dose before percutaneous coronary intervention: results of a double‐blind, randomized clinical trial, J Interv Cardiol, 22, 368, 10.1111/j.1540-8183.2009.00486.x

Mehta, 2010, Double‐dose versus standard‐dose clopidogrel and high‐dose versus low‐dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT‐OASIS 7): a randomised factorial trial, Lancet, 376, 1233, 10.1016/S0140-6736(10)61088-4

Angiolillo, 2008, Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study, Thromb Haemost, 99, 161, 10.1160/TH07-09-0562

Palmerini, 2010, A randomised study comparing the antiplatelet and antiinflammatory effect of clopidogrel 150 mg day−1 versus 75 mg day−1 in patients with ST‐segment elevation acute myocardial infarction and poor responsiveness to clopidogrel: results from the DOUBLE study, Thromb Res, 125, 309, 10.1016/j.thromres.2009.06.016

Price MJ. Standard versus high‐dose clopidogrel according to platelet function testing after PCI: results of the GRAVITAS trial. Paper presented at: The American Heart Association’s Scientific Sessions; November 16, 2010; Chicago, USA.

Luinstra, 2010, PPI use in patients commenced on clopidogrel: a retrospective cross‐sectional evaluation, J Clin Pharm Ther, 35, 213, 10.1111/j.1365-2710.2009.01089.x

Bhindi, 2008, Interaction between statins and clopidogrel: is there anything clinically relevant?, Q J Med, 101, 915, 10.1093/qjmed/hcn089

Gilard, 2006, Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin, J Thromb Haemost, 4, 2508, 10.1111/j.1538-7836.2006.02162.x

Gilard, 2008, Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double‐blind OCLA (Omeprazole CLopidogrel Aspirin) study, J Am Coll Cardiol, 51, 256, 10.1016/j.jacc.2007.06.064

Siriswangvat, 2010, Comparison between the effect of omeprazole and rabeprazole on the antiplatelet action of clopidogrel, Circ J, 74, 2187, 10.1253/circj.CJ-09-0913

van Boxel, 2010, Cardiovascular and gastrointestinal outcomes in clopidogrel users on proton pump inhibitors: results of a large Dutch cohort study, Am J Gastroenterol, 105, 2430, 10.1038/ajg.2010.334

Gremmel, 2010, The influence of proton pump inhibitors on the antiplatelet potency of clopidogrel evaluated by 5 different platelet function tests, J Cardiovasc Pharmacol, 56, 532, 10.1097/FJC.0b013e3181f68209

Tentzeris, 2010, Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation, Thromb Haemost, 104, 1211, 10.1160/TH10-04-0218

Bhatt, 2010, Clopidogrel with or without omeprazole in coronary artery disease, N Engl J Med, 363, 1909, 10.1056/NEJMoa1007964

Bhatt, 2006, Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events, N Engl J Med, 354, 1706, 10.1056/NEJMoa060989

Bal Dit Sollier, 2010, Differential sensitivity and kinetics of response of different ex vivo tests monitoring functional variability of platelet response to clopidogrel, Thromb Haemost, 104, 571, 10.1160/TH09-11-0803

Angiolillo, 2007, ADP receptor antagonism: what’s in the pipeline?, Am J Cardiovasc Drugs, 7, 423, 10.2165/00129784-200707060-00005

Mousa, 2010, Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist, Clin Appl Thromb Hemost, 16, 170, 10.1177/1076029609355589